Department of Urology, University of Regensburg, St Josef Hospital, Regensburg, Germany

To evaluate the long-term efficacy of high-intensity focused ultrasound (HIFU) therapy for patients with localised prostate cancer.

Patients included in this multicentre analysis had T1-T2 NxM0 prostate cancer, a PSA<15ng/ml, and a Gleason score (GS) </= 7, and were treated with prototypes or first-generation Ablathermtrade mark HIFU devices between October 1997 and August 2001. The Phoenix definition of biochemical failure was used (PSA nadir+2). Treatment failure was defined as: biochemical failure or positive biopsy.

A total of 140 patients with a mean (SD) age 69.1 yr (6.6) were included. Mean (SD) follow-up was 6.4 yr (1.1). Control prostate biopsies were negative in 86.4% of patients. Median PSA nadir of 0.16ng/ml (range, 0.0-9.1) was achieved at a mean (SD) of 4.9 mo (5.2). A PSA nadir </= 0.5ng/ml was recorded in 68.4% of patients. The actuarial biochemical failure-free survival rates (SR) at 5 and 7 yr were 77% and 69%, respectively. The actuarial disease-free SR at 5 and 7 yr were 66% and 59%, respectively.

This study demonstrates the effective long-term cancer control achieved with HIFU in patients with low- or intermediate-risk localised prostate cancer.

Written by
Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A.

Reference
Eur Urol. 2007 Nov 5 [Epub ahead of print]
doi:10.1016/j.eururo.2007.10.062

PubMed Abstract
PMID:17997026

Read a Review of This Abstract on UroToday.com

UroToday.com Prostate Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!